Novartis receives FDA Breakthrough Therapy designations for investigational STAMP inhibitor asciminib (ABL001) in chronic myeloid leukaemia ... Feb 10
Strategic Collaboration to Accelerate Clinical Evaluation of Therapies for Patients with Leukemia... Sep 09
... Sep 08
-Advertisements-